Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Andreas Hochhaus, Jiří Mayer et al.|Blood|2013Cited by 391
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Timothy P. Hughes, Ilaria S. Pagani et al.|Blood|2020Cited by 86
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementSusan Branford, Timothy P. Hughes, Dong‐Wook Kim et al.|Blood|2012Cited by 49